Unilife — Q2 2011 Earnings Presentation
16 slides from Unilife's earnings presentation, Feb 14, 2011
Slide 1: Fiscal 2011 2nd Quarter Conference Call
February 14, 2011 Fiscal 2011 2nd Quarter Conference Call
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward- looking statements are based on management's beliefs and assumptions and on information currently available to our m
Slide 3: Q2 2011 Highlights
3 Q2 2011 Highlights Focus on building operational capabilities to meet demand Construction and relocation to York, PA facility completed Transfer of Unifill and Unitract automated assembly lines in progress Unifill industrialization program remains on track Entering phase of commercial production a
Slide 4: Appointment of Dr. Ramin Mojdeh as COO
Appointment of Dr. Ramin Mojdeh as COO Strong global industry leader in the design, development, production, sales and marketing of therapeutic and diagnostic medical devices Senior Executive of Becton Dickinson (BD) - prefilled syringe leader VP of BD Medical, Pharmaceutical Systems 2008-2010 VP of
Slide 5: Q2 2011 Financial Data
5 Richard Wieland Chief Financial Officer Q2 2011 Financial Data
Slide 6: Financial Data - Fiscal 2nd Quarter 2011
6 Financial Data - Fiscal 2nd Quarter 2011 Revenues for the quarter of $1.8m, compared to $3.2m for 2Q 2010 Unifill industrialization revenue decreased by $2.1m from 2Q 2010 Net loss for the quarter was $10.4m, or $0.19 per diluted share, compared to $5.9m, or $0.13 per diluted share, for 2Q 2010 R&
Slide 7: Financial Data - Fiscal 2nd Quarter 2011 (cont.)
Financial Data - Fiscal 2nd Quarter 2011 (cont.) Capital raising of A$35.9 million (US$35.3 million) A$23.1 million (US$22.3 million) from private placement in Australia A$12.8 million (US$13.0 million) from Share Purchase Plan (SPP) for Australian and New Zealand shareholders (heavily oversubscribe
Slide 8: Q2 2011 Highlights
8 Q2 2011 Highlights Alan Shortall Chief Executive Officer
Slide 9: Unilife's York, PA Facility
9 Unilife's York, PA Facility 165,000 sqf state-of-the-art facility and global headquarters Completed on-schedule within 12 months Capacity to produce up to 400m syringe units per year (Stage 1.) Video overview of the facility available at www.unilife.com
Slide 10: Inside the Facility: Reception Foyer
10 Inside the Facility Reception Foyer
Slide 11: Inside the Facility: Cleanroom for Unitract 1mL Packaging Line
11 Cleanroom for Unitract 1mL Packaging Line Inside the Facility
Slide 12: Inside the Facility: Fully segregated warehouse
12 Inside the Facility Fully segregated warehouse
Slide 13: Unitract 1mL syringes
13 Transition of line into new facility during Dec. 2010 Recertification of assembly line Cleanroom commissioning Production restarts this quarter Lewisberry inventory being used to support U.S launch program Supplying multiple U.S distributors New / repeat orders accelerating Rollout to IMCO distri
Slide 14: Unifill Ready-to-Fill Syringe
14 Factory acceptance testing for Unifill assembly system in process Key sections of assembly system already shipped and installed at York facility this quarter Initial production remains on track to commence this quarter Initial supply and sales to pharmaceutical customers remains on track to comme
Slide 15: Pharmaceutical Relationships Update
Pharmaceutical Relationships Update Various stages of discussion with more than a dozen companies Discussions continuing to accelerate favorably on several fronts Funding and revenue-generating opportunities for Unilife include: Sale of Unifill syringe to sanofi-aventis Sale of Unifill syringe to ot
Slide 16: Questions
uniuire®? Questions